Prelude Capital Management’s Alder Biopharmaceuticals ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-2,914
| Closed | -$55K | – | 2439 |
|
|
2019
Q3 | $55K | Buy |
+2,914
| New | +$33.3K | ﹤0.01% | 1138 |
|
|
2018
Q1 | – | Sell |
-48,767
| Closed | -$558K | – | 1841 |
|
|
2017
Q4 | $558K | Sell |
48,767
-6,052
| -11% | -$67.6K | 0.04% | 391 |
|
|
2017
Q3 | $672K | Sell |
54,819
-31,873
| -37% | -$332K | 0.06% | 313 |
|
|
2017
Q2 | $993K | Buy |
86,692
+71,504
| +471% | +$1.32M | 0.09% | 221 |
|
|
2017
Q1 | $316K | Buy |
+15,188
| New | +$336K | 0.03% | 423 |
|
|
2016
Q4 | – | Sell |
-16,162
| Closed | -$530K | – | 1909 |
|
|
2016
Q3 | $530K | Buy |
+16,162
| New | +$492K | 0.06% | 300 |
|
|
2016
Q1 | – | Sell |
-7,000
| Closed | -$231K | – | 1655 |
|
|
2015
Q4 | $231K | Buy |
7,000
+5,800
| +483% | +$196K | 0.04% | 494 |
|
|
2015
Q3 | $39K | Hold |
1,200
| – | – | 0.01% | 1120 |
|
|
2015
Q2 | $64K | Buy |
1,200
+500
| +71% | +$18.2K | 0.01% | 1062 |
|
|
2015
Q1 | $20K | Sell |
700
-400
| -36% | -$11K | ﹤0.01% | 1752 |
|
|
2014
Q4 | $32K | Buy |
+1,100
| New | +$19.7K | ﹤0.01% | 1606 |
|
Prelude Capital Management's ALDR Position: Q4 2019 in Review
Prelude Capital Management sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 2,914 shares — an estimated $55K sold.
Prelude Capital Management first reported a position in ALDR in Q4 2014 and held it in 11 quarters. The position peaked at $993K in Q2 2017. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.
- Prelude Capital Management reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- Prelude Capital Management sold 2,914 Alder Biopharmaceuticals shares in Q4 2019, an estimated $55K.
- Prelude Capital Management first reported a position in Alder Biopharmaceuticals in Q4 2014 and held it in 11 quarters.
- Prelude Capital Management's Alder Biopharmaceuticals position peaked at $993K in Q2 2017.
- 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.
Based on Prelude Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.